There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immutep (IMMP) and Marinus (MRNS) with bullish sentiments.
Immutep (IMMP)
Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Immutep today and set a price target of $5.00. The company’s shares closed last Monday at $2.12.
According to TipRanks.com, Cross is a 3-star analyst with an average return of 3.3% and a 37.8% success rate. Cross covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Syros Pharmaceuticals, and Aldeyra Therapeutics.
Currently, the analyst consensus on Immutep is a Moderate Buy with an average price target of $3.50, implying a 63.6% upside from current levels. In a report issued on November 3, Maxim Group also assigned a Buy rating to the stock with a $2.00 price target.
See today’s analyst top recommended stocks >>
Marinus (MRNS)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus today and set a price target of $20.00. The company’s shares closed last Monday at $13.71.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of 12.5% and a 33.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $29.25, an 112.9% upside from current levels. In a report issued on November 1, Oppenheimer also maintained a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
